ArticleTransplant international : official journal of the European Society for Organ Transplantation2026
ABO-incompatibility and hepatocellular carcinoma recurrence after living donor liver transplantation: stratified by tumor burden.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ABO-incompatible (ABOi) living donor liver transplantation (LDLT) requires rituximab-based desensitization and intensified early immunosuppression, and whether this promotes hepatocellular carcinoma (HCC) recurrence remains controversial. We hypothesized that this effect depends on tumor burden, assessed morphologically (Milan criteria) and biologically (ADV score). In this single-center study, we analyzed 1,573 adults transplanted for HCC (ABOi, n = 316; ABO-compatible [ABOc], n = 1,257); the primary endpoint was recurrence-free survival (RFS). Crude recurrence was similar (21.8% vs. 20.7%; P = 0.64) despite a lower tumor burden in ABOi recipients. In a propensity score-matched cohort, RFS did not differ overall (hazard ratio 1.11, 95% CI 0.82-1.48), but beyond Milan recurrence was higher in ABOi recipients (53.7% vs. 38.5%; adjusted HR 1.45, 95% CI 1.00-2.09), whereas within Milan it was identical (13.3% vs. 13.4%). The same pattern held for tumor biology: recurrence was higher in ABOi only at ADV ≥5log (64.0% vs. 44.6%; P = 0.022). Higher early tacrolimus exposure in ABOi recipients was associated with recurrence. Overall survival was similar (P = 0.91). ABO-incompatibility did not compromise survival. Recurrence was higher in ABOi recipients with a high tumor burden by either measure, although the formal interaction tests were not significant (P = 0.23 and P = 0.088). These exploratory subgroup findings are hypothesis-generating and support closer early surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.